Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and Integral Molecular, a developer of antibodies against membrane proteins, have partnered to offer complementary expertise to their respective customers to better assess the risks of off-target binding of biologic drug candidates.   Unwanted immunogenicity can have severe consequences for patients and jeopardize drug development programs. Therefore, de-risking therapeutics by assessing thei...